Albrechtsen
board of director
CombiGene
Sweden
Biography
Morten Albrechtsen Born 1964, has long experience of CNS drug development including Alzheimer's disease (for Enkam), depression (Boehringer Ingelheim), Newcomed / Saniona, pain control (Nycomed), insomnia (Blake Insomnia Inc. / Sleep) and stroke (Boehringer Ingelheim, Enkam). His experience ranges from preclinical and clinical development to regulatory affairs and commercialization, and includes both biological products and small molecules
Research Interest
medicine
